Skip to main content

NCCIH Workshop 2020: Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes

Date: October 23, 2020 - 09:45 a.m. ET to 3:00 p.m. ET

Videocast

Meeting Minutes

Event Description

The overall goals of this workshop are two fold—one is to convene principal investigators funded by NCCIH on the topic of the analgesic properties of minor cannabinoids and terpenes from natural products and the underlying mechanisms; and the other is to discuss current research barriers and opportunities on this topic. This workshop is aligned with NCCIH’s mission to support research on the fundamental science, safety, and usefulness of complementary and integrative health approaches. Specifically, minor cannabinoids and terpenes from natural products are part of complementary interventions supported by NCCIH. The workshop is also aligned with NCCIH’s strategic goals of advancing understanding of basic biological mechanisms of action of natural products and improving care for hard-to-manage symptoms, such as pain. The meeting will not be archived.

An abstract interpretation of minor cannabinoids and terpenes.

Meeting Summary

View the program book for a complete agenda, speaker bios and abstracts, and panelist bios. 

A meeting summary for the Annual Principal Investigators’ Meeting 2020 is available:

Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (173 KB PDF).

Agenda

9:459:50 a.m. | Welcome From the National Center for Complementary and Integrative Health (NCCIH)

  • David Shurtleff, Ph.D., Deputy Director, NCCIH

9:5010:00 a.m. | Meeting Overview and Goals

  • Emmeline Edwards, Ph.D., Director, NCCIH Division of Extramural Research

10:0011:00 a.m. | Data Blitz Presentations on the Nonclinical Studies Funded by NCCIH Cannabinoids and Pain Funding Opportunity Announcements

  • Sara Jane Ward, Ph.D., Temple University of the Commonwealth, “Analgesic Efficacy of Single and Combined Minor Cannabinoids and Terpenes
  • Yu-Shin Ding, Ph.D., New York University School of Medicine, “Identifying the Mechanisms of Action for CBD on Chronic Arthritis Pain
  • Andrew D. Ellington, Ph.D., University of Texas at Austin, “Synthetic Biology for the Chemogenetic Manipulation of Pain Pathways
  • Cassandra L. Quave, Ph.D., Emory University, “Mechanistic Studies on Analgesic Effects of Terpene Enriched Extracts From Hops
  • David Sarlah, Ph.D., University of Illinois, “Systematic Investigation of Rare Cannabinoids With Pain Receptors
  • Jenny L. Wiley, Ph.D., Research Triangle Institute, “Minor Cannabinoids and Terpenes: Preclinical Evaluation as Analgesics
  • Zhigang He, Ph.D., B.M., Boston Children’s Hospital/Harvard Medical School, “Mechanism and Optimization of CBD-Mediated Analgesic Effects

Q & A Session on Nonclinical Studies

Moderator: Inna Belfer, M.D., Ph.D., NCCIH

11:0011:15 a.m. | Break

11:15 a.m.Noon | Data Blitz Presentations on the Clinical Studies Funded by NCCIH Cannabinoids and Pain Funding Opportunity Announcements

  • Rajiv Radhakrishnan, M.B.B.S., M.D., Yale School of Medicine, “Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization
  • Deborah Yurgelun-Todd, Ph.D., University of Utah, “Exploring the Mechanisms Underlying the Analgesic Effect of Cannabidiol Using Proton Magnetic Resonance Spectroscopy
  • Judith Hellman, M.D., University of California, San Francisco, “Neuro-Immune Mechanisms of Minor Cannabinoids in Inflammatory and Neuropathic Pain
  • Ziva D. Cooper, Ph.D., University of California, Los Angeles, “Analgesic and Subjective Effects of Terpenes Administered Alone and in Combination With THC: Potential THC- and Opioid-Sparing Effects of Myrcene and β-Caryophyllene
  • Richard E. Harris, Ph.D., University of Michigan at Ann Arbor, “Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

Q & A Session on Clinical Studies

Moderator: Angela Arensdorf, Ph.D., NCCIH

Noon1:00 p.m. | Break

1:001:30 p.m. | Keynote Presentation (Introduction by David Shurtleff, Ph.D., NCCIH)

Cannabis Research in Canada: Opportunities, Risks, and Lessons Learned

Mark A. Ware, M.B.B.S., MRCP(UK), M.Sc., Chief Medical Officer, Canopy Growth Corporation, Canada; Associate Member, McGill University

1:301:45 p.m. | Q & A Session for Keynote Speaker

Moderator: Emmeline Edwards, Ph.D., NCCIH

1:452:30 p.m. | Panel Discussion on Gaps and Future Directions

  • Inna Belfer, M.D., Ph.D., NCCIH
  • Roger Little, Ph.D., National Institute on Drug Abuse (NIDA)
  • Jeffrey White, M.D., National Cancer Institute (NCI)
  • Qi-Ying Liu, M.D., M.Sci., National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • Smriti Iyengar, Ph.D., National Institute of Neurological Disorders and Stroke (NINDS)
  • Mi Hillefors, M.D., Ph.D., National Institute of Mental Health (NIMH)
  • Dominic Chiapperino, Ph.D., Food and Drug Administration (FDA)
  • Terrence L. Boos, Ph.D., Drug Enforcement Administration (DEA)
  • Robert Walsh, R.A.C., NIDA Drug Supply Program

2:303:00 p.m. | Q & A Session for the Panelists

Moderator: David Shurtleff, Ph.D., NCCIH

3:00 p.m. | Adjournment